Brief: Alzinova: New Positive Safety Review Of Phase 1B Study For ALZ-101 Vaccine

Alzinova AB

16/03/2023 07:15

March 16 (Reuters) - Alzinova AB  ALZ.ST :
    * ALZINOVA: NEW POSITIVE SAFETY REVIEW OF THE PHASE 1B STUDY
FOR
THE ALZ-101 VACCINE
    * PLANNED EXTERNAL SAFETY REVIEW HAS BEEN CONDUCTED OF
COMPANY'S
CLINICAL PHASE 1B STUDY - WITH A POSITIVE ASSESSMENT TO CONTINUE
STUDY AS PLANNED.
    * DSMB RECOMMENDS CONTINUING STUDY AS PLANNED AND THAT STUDY
CAN
ALSO BE EXTENDED IF COMPANY SO DECIDES.

Source text for Eikon:  ID:nMFN2v6bGQ 
Further company coverage:  ALZ.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))